Global Erectile Dysfunction (ED) Drugs Market US$ 4.1 Billion by 2021

Global Erectile Dysfunction (ED) Drugs Market US$ 4.1 Billion by 2021

According to a new market research report published by iHealthcareAnalyst, Inc., Erectile Dysfunction Drugs Market – Global ED Drugs and Pipeline Analysis and Forecast 2017-2021, the global erectile dysfunction (ED) drugs market is estimated to reach nearly US$ 4.2 Billion in 2020.

Visit the Erectile Dysfunction Drugs Market – Global ED Drugs and Pipeline Analysis and Forecast 2017-2021 report at https://www.ihealthcareanalyst.com/report/erectile-dysfunction-drugs-market/

Diseases, nutritional status, trauma, surgical procedures, or medications can affect erectile function by altering the nervous, vascular, or hormonal systems. Phosphodiesterase-5 (PDE-5) inhibitors are one of the most widely used and effective types of medication for treating erectile dysfunction. The erectile dysfunction (ED) drugs market report estimates the market size (Revenue US$ million – 2014 to 2021) for key market segments based on the drug type by major brands such as Cialis (tadalafil), Helleva (lodenafil carbonate), Levitra/Staxyn (vardenafil), MUSE (Medicated Urethral System for Erection), Mvix (mirodenafil), Stendra/Spedra (avanafil), Viagra (sildenafil citrate), Zydena (udenafil), etc. and clinical pipeline analysis of phase 1, 2 and 3 drugs such as Uprima (apomorphine), Vitaros (alprostadil), and forecasts growth trends (CAGR% – 2017 to 2021). It also provides the detailed market landscape and profiles of major competitors in the global market including company overview, financial snapshot, major products and services offered, and recent trends in strategic management.

The global erectile dysfunction (ED) drugs market is segmented as:

  1. Drug (Brand) Type
    • Cialis (Tadalafil)
    • Helleva (Lodenafil Carbonate)
    • Levitra/Staxyn (Vardenafil)
    • MUSE (Medicated Urethral System for Erection)
    • Mvix (Mirodenafil)
    • Stendra/Spedra (Avanafil)
    • Viagra (Sildenafil Citrate)
    • Zydena (Udenafil)
  1. Pipeline Analysis (Phase 3 Drugs)
    • Uprima (Apomorphine)
    • Vitaros (Alprostadil)
    • Others (Topiglan, Melanocortin Activators, Gene Therapy)
  1. Geography (Region, Country)
    • North America (U.S., Canada)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Asia Pacific (Japan, China, India, Rest of APAC)
  1. Company Profiles
    • Apricus Biosciences, Inc.
    • Bayer AG
    • Cristalia Produtos Quimicos Farmaceuticos Ltda.
    • Dong-A Pharmaceutical Co. Ltd.
    • Eli Lilly and Company
    • Meda Pharmaceuticals, Inc.
    • Pfizer, Inc.
    • K. Chemicals Co. Ltd.
    • Vivus, Inc.

About Us

iHealthcareAnalyst, Inc. is a global health care market research and consulting company providing market analysis, and competitive intelligence services to global clients. The Company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.

iHealthcareAnalyst, Inc. provides industry participants and stakeholders with strategically analyzed, unbiased view of market dynamics and business opportunities within its coverage areas.

Contact Us

iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Email: [email protected]
Website: https://www.ihealthcareanalyst.com

2017-11-05T19:11:16+00:00 Categories: Press Releases|